Extract
我们感谢o . Moran-Mendoza和同事的interest in our recent publication on the prevalence of progressive pulmonary fibrosis (PPF) within the Canadian Registry for Pulmonary Fibrosis (CARE-PF) [1]. The authors have raised several important points, which we have summarised and addressed as follows.
Abstract
Readers should be aware of both the advantages and limitations of data drawn from prospective registries.https://bit.ly/40V3TK7
Footnotes
Conflict of interest: C.J. Ryerson reports support for the present manuscript from Boehringer Ingelheim; grants from Boehringer Ingelheim and Hoffmann-La Roche; consulting fees from Boehringer Ingelheim, Hoffmann-La Roche, AstraZeneca, Veracyte, Ensho and Pliant Therapeutics; lecture honoraria from Boehringer Ingelheim, Hoffmann-La Roche and Cipla Ltd; travel support from Cipla Ltd and Boehringer Ingelheim; outside the submitted work.
Conflict of interest: N. Hambly reports grants from Boehringer Ingelheim and Janssen; lecture honoraria and travel support from Boehringer Ingelheim, Janssen and Roche; outside the submitted work.
Conflict of interest: M. Kolb reports support for the present manuscript from Boehringer Ingelheim; grants from Boehringer Ingelheim, Pieris and Roche; consulting fees from Boehringer Ingelheim, Roche, Horizon, Cipla, Abbvie, Bellerophon, Algernon, CSL Behring, United Therapeutics, LabCorp and ShouTi; lecture honoraria from Roche, Novartis, Boehringer Ingelheim; payment for expert testimony from Roche; advisory board participation from United Therapeutics and LabCorp; and reports an allowance as Chief EditorERJ.
- ReceivedFebruary 7, 2023.
- AcceptedFebruary 8, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contactpermissions{at}ersnet.org